A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?
Crossref DOI link: https://doi.org/10.1007/s10067-017-3588-7
Published Online: 2017-03-01
Published Print: 2017-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Harrold, Leslie R.
Litman, Heather J.
Connolly, Sean E.
Kelly, Sheila
Hua, Winnie
Alemao, Evo
Rosenblatt, Lisa
Rebello, Sabrina
Kremer, Joel M.
Funding for this research was provided by:
Bristol-Myers Squibb
License valid from 2017-03-01